Current Edition


Novartis ups investment in gene therapy for the eye with $800M buyout

Novartis’ offer comes three months after Gyroscope presented at a medical meeting early data from 13 patients who had been dosed with the gene therapy, …

Continue Reading →

How Bayer lured a biotech away from an IPO and into a buyout

In what has become a common move by large pharmaceutical companies attempting to revitalize their drug research, German healthcare conglomerate Bayer has acquired a small …

Continue Reading →